Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$211.63 +0.6%	$196.10	$163.81 ▼ $218.66	$371.68B	0.53	4.21 million shs	4.33 million shs
ISRG Intuitive Surgical	$469.07 -0.9%	$499.62	$425.00 ▼ $616.00	$169.67B	1.61	1.74 million shs	2.23 million shs
META Meta Platforms	$735.11 -0.5%	$737.00	$479.80 ▼ $796.25	$1.86T	1.24	9.49 million shs	9.29 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	0.00%	+1.29%	+7.73%	+12.33%	+7.10%
ISRG Intuitive Surgical	0.00%	+1.04%	-2.03%	-14.23%	-3.92%
META Meta Platforms	0.00%	-1.94%	-1.51%	+10.77%	+41.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.627 of 5 stars	2.5	3.0	3.3	3.9	2.7	2.5	1.9
ISRG Intuitive Surgical	4.9533 of 5 stars	4.3	3.0	0.0	4.0	3.0	2.5	3.1
META Meta Platforms	4.3011 of 5 stars	3.5	3.0	1.7	0.0	2.9	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$214.95	1.57% Upside
ISRG Intuitive Surgical	2.60	Moderate Buy	$595.95	27.05% Upside
META Meta Platforms	2.96	Moderate Buy	$822.41	11.88% Upside

Current Analyst Ratings Breakdown

Latest ABBV, META, and ISRG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	ABBV AbbVie	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/22/2025	ISRG Intuitive Surgical	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell
8/20/2025	ISRG Intuitive Surgical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/19/2025	ISRG Intuitive Surgical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$615.00
8/19/2025	META Meta Platforms	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	META Meta Platforms	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$920.00
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$231.00
8/11/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2025	ABBV AbbVie	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2025	ABBV AbbVie	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$214.00
8/5/2025	META Meta Platforms	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$888.00 ➝ $980.00

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.64	$15.02 per share	14.09	($0.08) per share	-2,645.38
ISRG Intuitive Surgical	$8.35B	20.13	$7.92 per share	59.25	$50.08 per share	9.37
META Meta Platforms	$164.50B	11.23	$30.58 per share	24.04	$77.65 per share	9.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	100.78	15.14	1.35	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
ISRG Intuitive Surgical	$2.32B	$7.17	65.42	61.48	4.96	28.51%	14.56%	12.93%	10/16/2025 (Estimated)
META Meta Platforms	$62.36B	$27.62	26.62	24.33	1.53	39.99%	39.33%	25.83%	10/29/2025 (Estimated)

Latest ABBV, META, and ISRG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/30/2025	Q2 2025	META Meta Platforms	$5.75	$7.14	+$1.39	$7.14	$44.55 billion	$47.52 billion
7/22/2025	Q2 2025	ISRG Intuitive Surgical	$1.93	$2.19	+$0.26	$1.81	$2.35 billion	$2.44 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.10%	N/A	312.38%	53 Years
ISRG Intuitive Surgical	N/A	N/A	N/A	N/A	N/A
META Meta Platforms	$2.10	0.29%	N/A	7.60%	1 Years

Latest ABBV, META, and ISRG Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
ISRG Intuitive Surgical	N/A	5.17	4.18
META Meta Platforms	0.15	1.97	1.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ISRG Intuitive Surgical	83.64%
META Meta Platforms	79.91%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
ISRG Intuitive Surgical	0.70%
META Meta Platforms	13.61%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.77 billion	Optionable
ISRG Intuitive Surgical	15,638	358.48 million	355.97 million	Optionable
META Meta Platforms	74,067	2.51 billion	2.17 billion	Optionable

ABBV, META, and ISRG Headlines

Recent News About These Companies

ChatGPT history by a teenager is seen at a coffee shop in Russellville, Ark

OpenAI and Meta say they're fixing AI chatbots to better respond to teens in distress

...

September 2 at 11:21 AM | marketbeat.com

Meta Platforms, Inc. $META Shares Sold by Ashton Thomas Securities LLC

September 2 at 8:04 AM | marketbeat.com

Meta Platforms, Inc. $META Shares Acquired by First Manhattan CO. LLC.

September 2 at 8:04 AM | marketbeat.com

Meta Platforms, Inc. $META Stake Boosted by GW Henssler & Associates Ltd.

September 2 at 7:51 AM | marketbeat.com

Meta Platforms, Inc. $META Shares Sold by Cigna Investments Inc. New

September 2 at 7:41 AM | marketbeat.com

1248 Management LLC Sells 1,013 Shares of Meta Platforms, Inc. $META

September 2 at 7:40 AM | marketbeat.com

Maverick Capital Ltd. Invests $100.51 Million in Meta Platforms, Inc. $META

September 2 at 7:29 AM | marketbeat.com

Newbrook Capital Advisors LP Has $22.17 Million Stock Holdings in Meta Platforms, Inc. $META

September 2 at 7:29 AM | marketbeat.com

Focus Partners Advisor Solutions LLC Acquires 2,238 Shares of Meta Platforms, Inc. $META

September 2 at 7:21 AM | marketbeat.com

First Financial Bankshares Inc Reduces Stock Position in Meta Platforms, Inc. $META

September 2 at 7:21 AM | marketbeat.com

Ameriflex Group Inc. Grows Position in Meta Platforms, Inc. $META

September 2 at 6:57 AM | marketbeat.com

Atreides Management LP Acquires Shares of 239,789 Meta Platforms, Inc. $META

September 2 at 6:50 AM | marketbeat.com

Unisphere Establishment Has $15.56 Million Position in Meta Platforms, Inc. $META

September 2 at 6:50 AM | marketbeat.com

EP Wealth Advisors LLC Sells 1,923 Shares of Meta Platforms, Inc. $META

September 2 at 6:27 AM | marketbeat.com

Contour Asset Management LLC Acquires New Position in Meta Platforms, Inc. $META

September 2 at 6:27 AM | marketbeat.com

Meta Platforms, Inc. (NASDAQ:META) Given Average Rating of "Moderate Buy" by Brokerages

September 2 at 2:49 AM | marketbeat.com

Can META's Focus on AI-Optimized Data Centers Push the Stock Higher?

September 1 at 1:41 PM | zacks.com

Meta Platforms, Inc. $META Shares Purchased by Flputnam Investment Management Co.

September 1 at 9:41 AM | marketbeat.com

QVT Financial LP Takes Position in Meta Platforms, Inc. $META

September 1 at 9:40 AM | marketbeat.com

Point72 Italy S.r.l. Has $2 Million Stock Position in Meta Platforms, Inc. $META

September 1 at 9:40 AM | marketbeat.com

Point72 Europe London LLP Has $96.03 Million Stake in Meta Platforms, Inc. $META

September 1 at 9:39 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABBV, META, and ISRG Company Descriptions

AbbVie NYSE:ABBV

$211.63 +1.23 (+0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$211.65 +0.02 (+0.01%)

As of 07:55 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Intuitive Surgical NASDAQ:ISRG

$469.07 -4.23 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$467.50 -1.57 (-0.33%)

As of 07:59 PM Eastern

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Meta Platforms NASDAQ:META

$735.11 -3.59 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$738.68 +3.56 (+0.48%)

As of 08:00 PM Eastern

Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time